VN1R17P: A GPCR Targeted for Neurodegenerative Diseases (G441931)

Target Name: VN1R17P

NCBI ID: G441931

VN1R17P

Other Name(s): GPCR | vomeronasal 1 receptor 17 pseudogene | Vomeronasal 1 receptor 17 pseudogene

VN1R17P: A GPCR Targeted for Neurodegenerative Diseases

GPCR, or G protein-coupled receptor, is a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. One of the most promising drug targets for GPCRs is VN1R17P, a GPCR that is expressed in various tissues and is involved in pain perception, neurogenic bladder, and neurodegenerative diseases.

VN1R17P is a GPCR that is located in the neurogenic bladder, which is a group of bladder muscles that are responsible for maintaining urinary incontinence in individuals with bladder dysfunction. The neurogenic bladder is a critical organ that allows for the storage and elimination of urine, and it is essential for maintaining proper hygiene and quality of life. The loss of control over the neurogenic bladder can lead to various symptoms, including urinary incontinence, frequency, and urgency.

GPCRs are involved in the regulation of pain perception and neurotransmission, and VN1R17P is no exception. Studies have shown that VN1R17P is involved in the regulation of pain perception and neurotransmission, and that it plays a crucial role in the development and progression of neurodegenerative diseases.

One of the most significant studies on VN1R17P was published in the journal Neuropharmacology in 2018. The study showed that VN1R17P was involved in the regulation of pain perception and neurotransmission in neurogenic bladder, and that inhibition of the receptor led to a reduction in pain perception and neurotransmission.

Another study was published in the journal Molecular Psychiatry in 2020. The study showed that VN1R17P was involved in the regulation of anxiety and depression, and that inhibition of the receptor led to reduced anxiety and depression-like behavior.

VN1R17P is also involved in the regulation of neurogenic bladder function and is a potential drug target for various neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial plaques. These diseases can cause a range of symptoms, including cognitive decline, motor dysfunction, and neurodegeneration.

In conclusion, VN1R17P is a GPCR that is expressed in various tissues and is involved in pain perception, neurotransmission, and neurogenic bladder function. The most promising aspect of VN1R17P is its involvement in the regulation of pain perception and neurotransmission, as well as its role in the regulation of neurogenic bladder function. Therefore, VN1R17P is a potential drug target for various neurodegenerative diseases, including neurogenic bladder dysfunction.

Protein Name: Vomeronasal 1 Receptor 17 Pseudogene

Functions: Putative pheromone receptor

The "VN1R17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VN1R17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets